Scholars Central

Conference abstractPublished 30 Nov 2015

Post-Infectious Autoimmune Syndrome (PIFAS) as an integrated and combinatorial biomarker to monitor autoimmune myocarditis and thus the chronification of post-infectious diseases of autoimmune origin

Authors: Sergey Suchkov, Natalie Cherepahina, Murat Agirov, Trevor Marshall, Kusum Ah-medilova, Jamiliya Tabaksoeva

I.M.Sechenov First Moscow State Medical University, Russia; A.I.Evdokimov Moscow State Medical & Dental University, Russia; Central Clinical Hospital No 85, Russia; Moscow Municipal Clinical Hospital No 83, Russia; EPMA, EU; ISPM, Japan; PMC

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Development of PIFAS as a Post-Infectious Autoimmune Syndrome (PIFAS) to illustrate a new combinatorial and integrated biomarker of the immune-mediated (including latent) disorders is featured with a progression of chronic relapsing diseases of post-infectious origin. We have investigated the syndrome-like immunopathology as applicable to chronic inflammatory processes including chronic myocarditis. In view of the structural homology immune response caused by a microbial pathogen to balance between two categories of epitopes (self-epitopes and microbial epitopes) is being developed through both autoreactive T-cells and auto-Abs. The identification of such pathogen is restricted by some difficulties. Thus, for Auto Immune Myocarditis (AIM) to make a bridging link with the infection is established for two-thirds of all patients, and transformation of primary (infectious) phase into PIFAS is initiated by mimicking epitopes of, for instance, Coxsackievirus (CVB3) and/or Herpesviridae (CMV), herewith presence of cardiomyosine autoreactive CTLs (CM-auto reactive CTLs) and anti-CM auto-Abs, damaging myocardium to release sequestered autoAgs and to facilitate the induction and/or development of PIFAS is required. We can stress that a tandem of two mutually mimicking epitopes (microbial and self-epitopes) is implicated in the pathogenesis of PIFAS. The therapeutic strategy for such patients should be different. And the identification of the primary pathogen or microbial associate is no less important part of the protocol being used, for what we applied immunodiagnostic screening combined with molecular diagnostics. There are no obvious clinical and laboratory criteria to get the syndrome validated. An application of transgenic models to suit the aims of clinical practice will give an opportunity to reveal the events gapped between induction and progressing of PIFAS and will allow to pre-select specific targets to control induction and progression of PIFAS and thus chronification of the clinical illness to prevent the latter in time.

Subjects

Cardiology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Clinical and Experimental Cardiology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical and Experimental Cardiology
  • SubjectCardiology
  • BylineArticles whose byline prints “Sergey Suchkov”
  • BylineArticles whose byline prints “Natalie Cherepahina”
  • BylineArticles whose byline prints “Murat Agirov”
  • BylineArticles whose byline prints “Trevor Marshall”
  • BylineArticles whose byline prints “Kusum Ah-medilova”
  • BylineArticles whose byline prints “Jamiliya Tabaksoeva”